Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B. Atkins(Georgetown University), Hans J. Hammers(The University of Texas Southwestern Medical Center)
Cited by 30
Related Papers
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
|Journal of Clinical Oncology|2022|427
<scp>PD</scp>‐1 as a potential target in cancer therapy
|Cancer Medicine|2013|409